Skip to content
Keeping Current cover art

All Episodes

Keeping Current — 632 episodes · page 5 of 7

#
Title
401

Immunotherapies in Relapsed/Refractory Multiple Myeloma: 2021 Round-Up and a Look Into the Future

402

The COVID-19 mRNA Vaccines: How Do They Work?

403

Screening for Nonalcoholic Steatohepatitis in the Patient With Metabolic Disorders

404

Evolving Best Practices for Managing AL Amyloidosis: Sharing Perspectives

405

Throughout a Lifetime: The Intersection of HIV and Biological Considerations in Women Living With HIV

406

Evolution or Revolution in HFrEF: What Now for Our Patients?

407

Early-Onset Schizophrenia in a New Light: A Patient's Testimony

408

Beyond Post-Herpetic Neuralgia: Awareness of Other Complications Associated with Herpes Zoster

409

Beyond Clinical Trials: What Does Real-World Evidence Tell Us About COVID-19 mRNA Vaccine Effectiveness and Safety?

410

To Boost or Not to Boost: What Does the Evidence Tell Us?

411

Recognizing the Risk of Herpes Zoster in Older Adults With Comorbidities

412

Failure to Recover CD4 in People Living With HIV: Clarifying the Causes and Related Consequences

413

Stepping Stones to Long-Term Obesity Management

414

Improving on the Past: Using Next-Generation BTK Inhibitors Effectively in B-Cell Malignancies

415

News on NASH – Selected Highlights from The Liver Meeting 2021

416

SGLT2 Inhibitors and Other Classes of Therapies in HFpEF: Examining The Totality of Clinical Data

417

Reviewing Outcomes for HFpEF With SGLT2 Inhibitors: A Data Deep Dive

418

Dengue: Strategies to Limit Human Exposure to Disease-Carrying Mosquitos

419

New Treatment Approaches for Geographic Atrophy: Focus on the Complement Cascade

420

Novel Dual GIP/GLP-1 Receptor Agonists: The Future Standard of Diabetes Care?

421

Examining the Latest European HFrEF Guidelines: Putting the Patient at the Center of Management

422

Sorting Out Sore Throats: Role of Nonsteroidal Anti-Inflammatory Lozenges

423

Diabetes Dialogue: Incretin Therapy According to Guidelines

424

Breast Cancer in 2021: Where Do We Stand, and What Is Yet to Come?

425

Updates in Chronic Spontaneous Urticaria From EADV: Experts Highlight the Latest Advances

426

Emerging Science Across the Spectrum of Breast Cancer: Latest Perspectives

427

HFrEF Guideline Recommendations in Practice: Living Life Forward

428

My Patient on Hemodialysis Has Itch Symptoms: How Concerned Should I Be?

429

HIV and Inflammation: Raising Awareness of the Impact of Inflammation on People Living With HIV

430

Walking Through the Major Changes in Heart Failure: Definitions, Guidelines, and Impact of Management

431

Fundamental Facts About Glucagon-Like Peptide-1 Receptor Agonists for the Diabetologist – Quick Questions / Rapid Replies

432

B-Cell Malignancies: Why Not All BTK Inhibitors Are Created Equal

433

Optimizing the Nutritional Care of Preterm Infants

434

Updated Guidelines for Heart Failure With Reduced Ejection Fraction: Squinting Through the Fog

435

Zooming in on Cardiovascular Risk Control With Glucagon-Like Peptide-1 Receptor Agonists in Diabetes

436

Optimizing Outcomes in Diabetic Macular Edema: Why Fluid Matters

437

Can You Recognize and Diagnose CKD-aP?

438

Managing Cardiometabolic & COVID-19 Risks in Diabetes – A Vital News Bulletin for the Cardiologist

439

Challenges and Opportunities in the Management of Psoriasis: The Evolving Treatment Landscape

440

Neurodevelopmental Outcomes and Nutritional Strategies in Infants

441

Emerging Systemic Treatment Options Across the Spectrum of Breast Cancer Therapy

442

Understanding Geographic Atrophy: Disease Facts, Pathophysiology, Diagnosis, and Monitoring

443

Vitreoretinal Surgery Considerations for Novel Drug Technologies

444

Managing the Patient With DME: What's on the Horizon?

445

Mosquito-Borne Viral Diseases: Advice for Travelers to Endemic Areas

446

The Paramount Principles of Incretin Therapy: A Formula for Success in Primary Care

447

Why Should We Test for Lipoprotein(a)? The Experts Discuss

448

The Foundations of Immunization: What, Who, When and Why?

449

Changing Practice in Advanced/Metastatic Cholangiocarcinoma: What Clinicians Need to Know

450

From Genes to Cardiovascular Events: What All Physicians Need to Know About Lp(a)

451

Integrating Novel Therapies in the Management of Severe Asthma: Experts Discuss Challenging Cases

452

COPD: ICS Pros and Cons in Primary Care

453

Evolving Understanding on COVID-19 Vaccines and SARS-CoV-2 Variants

454

Essential Facts About Dual Incretin Receptor Agonists – Quick Questions, Rapid Replies

455

Succeeding Where No Other Therapy Has: SGLT2 Inhibition in HFpEF

456

Countdown to Clinical Knowledge of IL-17 Inhibitors in Psoriasis

457

Implementing New Lipid-Lowering Therapies Into Clinical Practice: 10 Frequently Asked Questions

458

Evolving Care Pathways in the Management of CRSwNP: Role of Biologics

459

Knowing Is Not Enough, We Must Apply: SGLT2 Inhibitors as Foundational Therapy for HFrEF

460

Vaccine Adjuvants: Levelling the Playing Field for Older Adults

461

MRD and FISH Testing in Patients With Multiple Myeloma: When and Why?

462

MRD and FISH Testing in Patients With Multiple Myeloma: When and Why?

463

nAMD: Poor Response -- When to Switch Therapies?

464

Implications of Immunosenescence for Immunization of Older Adults

465

Realizing the Opportunity of Molecularly Guided Therapy: How Do We Accelerate the Revolution?

466

siRNA Therapies in Dyslipidemia: A Clinical Primer

467

Lp(a) and Cardiovascular Risk: The New Kid on the Block

468

Treating Fever in Children: Calming "Fever Phobia" With Appropriate Antipyretic Therapy Guidance

469

COVID-19 Vaccines: The Beginning of the End?

470

The International Liver Conference – New Prospects for Dealing With NASH

471

Best Practices in the Management of Reflux Disease: Experts Discuss Patient Cases

472

Newly Approved Lipid-Lowering Therapies: The Top 5 Things to Know

473

Novel Immunotherapies in Relapsed/Refractory Multiple Myeloma: What Does the Future Hold?

474

Tailoring Management Strategies for My Patients With MS

475

Combination Therapy Choices in COPD -- State of the Art

476

Opportunities and Challenges in Early Breast Cancer: Do PARP Inhibitors Have a Role?

477

Advances in Chronic Lymphocytic Leukemia: New Data in Clinical Context

478

Dengue: Not Just 1 Virus, Not Just 1 Infection

479

Will New Treatments Transform Patient Care in nAMD and DME?

480

Taking the Next Step in Tackling Chronic Obesity: Insights From ECO 2021

481

Preventing HF After MI: What the Latest Data Tell Us

482

Intraocular Inflammation After Anti-VEGF Therapy: Latest Data and Guidance

483

Optimizing Access to Monoclonal Antibodies for COVID-19 Infection: The Global Perspective

484

My Patient's Cholesterol Is Still High Despite Treatment...Help!

485

What Is New in Biologic Therapy for Psoriasis: Updates From AAD

486

Putting International HF Treatment Pathways Into Practice: Willing Is Not Enough, We Must Do

487

Unfolding the Future of Chronic Spontaneous Urticaria: Emerging Data With Novel Therapies

488

Case Presentations in Severe Dengue: Contemporary Approaches to Clinical Management

489

The International Liver Conference – Ahead: NASH in Focus

490

The Role of SGLT2 Inhibitors in HFrEF Care: What Do the Latest Clinical Practice Documents Say?

491

New Molecularly Guided Therapies in Advanced/Metastatic Cholangiocarcinoma: What You Need to Know

492

Treating MS Early: Who, How, and When?

493

Bispecific Antibodies: The Case for Non-BCMA Targets

494

Tackling Adherence in Dyslipidemia: Concrete Actions for Better Outcomes

495

SARS-CoV-2 Vaccine Candidates: Expertise and Updates

496

Practical Strategies to Overcome Poor Vaccine Uptake During the COVID-19 Pandemic

497

COVID-19: The Path to Immunity

498

Optimal Implementation of the COVID-19 Vaccine: Best Practice and Strategies for Success

499

Beyond Clinical Trials: Treating nAMD in Clinical Practice

500

Molecularly Guided Therapy in Oncology Practice: The Evolving State of the Art